جستجوی استاد راهنمای دانشگاهی

Moustapha Saad El-Deen Kassem is an Affiliate Professor in the Department of Cellular and Molecular Medicine at the University of Copenhagen's Faculty of Health Sciences, and also holds a Professorship in Molecular Endocrinology at the University of Southern Denmark. His research focuses on mechanisms of impaired bone formation and bone fragility during aging and in osteoporosis, as well as molecular mechanisms of osteoblast differentiation from human skeletal stem cells (MSC). He combines clinical studies with cellular and molecular approaches, employing advanced genetics and proteomics technologies in molecular phenotyping of patient cohorts. His primary research interests include studying biological aging of MSC with respect to lineage fate determination, overcoming cellular senescent phenotype through genetic and non-genetic approaches, and investigating clinical applications of MSC in tissue regeneration for various diseases including fracture healing. His work has significant implications for understanding age-related bone loss and developing novel therapeutic interventions for osteoporosis. Analysis of his recent publications reveals a strong focus on microRNA regulation of stem cell differentiation, chromatin remodeling in cell fate determination, and molecular mechanisms controlling bone formation. His research spans from basic molecular mechanisms to clinical applications, with particular emphasis on how aging affects skeletal stem cell function and how these processes can be modulated for therapeutic benefit. The young investigator award, American Society for Bone and Mineral Research (1995) Award for best research project, Danish Society of Internal Medicine (1996) Generalkonsul Ernst Carlsens foundation award (2003) Research prize from Danish Free Masons Society (2004) Queen Ingrid's Lecture, Åbenrå Hospital (2008) Prize for outstanding scientific communication, University of Southern Denmark (2010) Marie & August Krogh award, Danish Medical Association (2012) SEB-Codan award, Danish Medical Association (2015) The Olav Thon award for Medical Research, University of Oslo, Norway (2019) Louis Avioli Founder Award, American Society for Bone and Mineral Research (2020) Professor Kassem has supervised 30 PhD students, 21 post-doctoral scientists, 16 Master students, 10 medical research students, and 3 bachelor students. His research has been continuously funded as principal investigator, with recent projects including studies on human stromal stem cells at single-cell resolution, enhancement of bone regeneration by targeting skeletal stem cells, and establishment of a German-Danish skeletal stem cell bank. He maintains active clinical work, spending 40% of his time at the endocrine and diabetes outpatient clinic at Odense University Hospital, and teaches endocrinology courses for biomedical students while providing instruction for medical students and junior physicians. His laboratory, the Kassem-Jafari Group, focuses on understanding the molecular basis of skeletal stem cell aging and differentiation, with particular emphasis on how these processes relate to age-related bone loss and potential regenerative therapies.

• Bone formation mechanisms
• Osteoporosis
• Stem cell biology
• +۵ مورد دیگر

Lise Nikolic Nielsen is a Professor (mso) and research group leader for veterinary clinical pathology and the veterinary diagnostic laboratory (VETLAB) at the University of Copenhagen's Department of Veterinary Clinical Sciences, Section for Internal Medicine, Oncology and Clinical Pathology. She has been a veterinarian since 2001 and has held various academic and research positions at the University of Copenhagen and other institutions. Her educational background includes: Veterinarian (DVM) from the Royal Veterinary and Agricultural University PhD in biomarkers in cancer in Bernese Mountain dogs from the University of Copenhagen (2006-2011) CertSAM (Specialist in Small Animal Medicine) Danish Recognised Specialist in companion animal internal medicine Professor Nielsen's research focuses on clinical pathology, which spans a wide area covering molecular markers in different types of biological material in living animals. Her specific research fields include identification of minimally invasive biomarkers for (early) disease detection in dogs and cats, validation of novel diagnostic and prognostic clinical biomarkers in a range of species, and investigation of the pathophysiological connection between haemostasis and inflammation in chronic medical and oncological conditions. Her work has significant implications for improving diagnostic approaches and understanding disease mechanisms in veterinary medicine. Her recent publications demonstrate expertise across multiple species (dogs, cats, horses) and conditions, with a particular emphasis on molecular diagnostics using microRNAs and other biomarkers. These publications show a consistent focus on translating basic science discoveries into clinically relevant diagnostic tools. Professor Nielsen leads VETLAB (https://vetdiagnostik.ku.dk/), which supports both University Veterinary Hospitals with diagnostic analyses, as well as clinical practices in Denmark, internal and external research units, and zoos in Denmark. Her laboratory serves as a critical bridge between clinical practice and research in veterinary medicine. She has taught pre- and post-graduate students since 2002. Currently, she teaches veterinary students in their 4th to 6th year, gives courses for veterinarians in clinical practice, and lectures both nationally and internationally. She has been involved in formalized research collaborations with Eiken A/S (Japan) and RefLab ApS (Denmark), and has had speaker engagements with various veterinary organizations including VETgruppen, IDEXX, Elanco (Denmark), Evidensia (Sweden), and ECVIM.

• Veterinary Clinical Pathology
• Biomarkers in cancer
• Minimally invasive biomarkers for disease detection in dogs and cats
• +۳ مورد دیگر

Dr Chris Young is a Senior Lecturer in Biomedical Science and Enterprise Lead for the School of Allied Health Sciences at De Montfort University's Faculty of Health and Life Sciences. He also serves as a long-term visiting scientist at the Li Ka Shing Cancer Research UK Research Institute, Addenbrookes, Cambridge, and maintains research collaborations with the University of Portsmouth. Dr Young completed his PhD in Molecular Medicine at the University of Portsmouth (2007-2011), an MSc in Genetic Manipulation and Molecular Cell Biology with Distinction from the University of Sussex (2006-2007), and a BSc in Biochemistry and Organic Chemistry with First Class Honours from The Open University (2003-2006). He also holds a PG-Cert in Learning and Teaching in Higher Education with Distinction (2019) and is a Fellow of the Higher Education Academy. Dr Young's research focuses on skeletal muscle pathologies and in vitro/in vivo modeling of human pathologies, with two main themes: elucidating the role of autophagy in skeletal muscle stem cells, and developing next-generation wound dressings for trauma and disaster medicine. His work on autophagy has therapeutic potential extending to muscle disease, muscle aging, soft tissue injuries, rhabdomyosarcoma, diabetes, and liver disease. His expertise in muscle pathology underpins his co-founded company, Chromar Research & Development Ltd., which customizes IP and technology for human and veterinary markets. Analysis of Dr Young's publication record reveals a strong focus on muscle pathology, particularly Duchenne Muscular Dystrophy, with significant contributions to understanding autophagy mechanisms and purinergic signaling. His recent work has expanded into cancer research, particularly colorectal cancer biomarkers, and medical education innovations, reflecting his diverse research interests and interdisciplinary approach. ICURe Discover, Explore & Exploit awardee for Chromar Research and Development Ltd. (2024-2025) VentureVersity selected case study for success in Enterprise and Innovation (2024) Shortlisted for Academy of Medical Sciences Early Career Award (2023) Blavatnik Award Nominee (2022) Elected Member of the Fisheries Society of the British Isles (2022-present) Member of the Royal Society of Biology (2021-present) Future Research Leader Scholarship (2020) Innovation for International Education Award from Nanolive (2019) Dr Young successfully supervises PhD students including Michal Kozielecki, Kyle Gordon, and Divine Derefaka, and has secured four successive externally funded innovation grants to support Chromar in the last two years. His teaching portfolio includes Chemistry for the Biosciences, Biochemistry and Molecular Cell Biology, Cyto & Histopathology, Clinical Biochemistry, Clinical Genetics, and Cancer Biology, where he serves as Module Lead for Research Projects and as 1st Year Coordinator and Timetabling Coordinator for Biomedical Science. Dr Young maintains an active laboratory focused on skeletal muscle pathologies with two main research themes. He is collaborating with Dr Omar Qutachi to spin out Chromar Research & Development Ltd. with Innovate UK ICURe funding support, demonstrating his commitment to translating research into practical applications for human and veterinary markets.

• Skeletal Muscle Pathologies
• Autophagy Mechanisms
• Purinergic Signaling
• +۶ مورد دیگر

Dr. Asta Baranauskaitė is an Associate Professor at the Lithuanian University of Health Sciences (LSMU), where she serves in the Rheumatology Clinic at the Medical Academy. With a Doctor of Science degree obtained in 1993, she has established herself as a prominent researcher in rheumatology, particularly in juvenile idiopathic arthritis (JIA) and rheumatoid arthritis. Her institutional affiliations include the Rheumatology Clinic (U525600), Medical Academy (MA), and LSMU Hospital Kaunas Clinics. Dr. Baranauskaitė's research focuses on advancing diagnostic and monitoring approaches for rheumatic diseases. She has made significant contributions to understanding biomarkers for JIA, including microRNAs and P-selectin, and has conducted pioneering work on the application of musculoskeletal ultrasound for detecting subclinical synovitis. Her research demonstrates that ultrasound can identify inflammation even during clinical remission, suggesting its value for comprehensive disease monitoring. She also participates in clinical trials comparing reference medications to biosimilars, particularly for rheumatoid arthritis treatments. Analysis of her recent publications reveals a strong emphasis on precision medicine approaches in rheumatology. Her work spans biomarker discovery, advanced imaging techniques, and comparative medication studies, with a consistent focus on improving diagnostic accuracy and treatment outcomes. The research shows particular attention to pediatric rheumatology while also addressing adult rheumatoid arthritis and related conditions. As a supervisor, Dr. Baranauskaitė mentors several junior researchers including Aušra Šnipaitienė, Andželika Šlegerytė, and Lina Jankauskaitė, who frequently appear as co-authors on her publications. Her collaborative approach extends across disciplines, working with experts in pediatrics, imaging, and laboratory sciences to address complex questions in rheumatology. Her research program demonstrates consistent productivity with numerous publications in 2024-2025, indicating active engagement in both clinical research and academic responsibilities. The work shows particular strength in methodologically rigorous studies including randomized controlled trials, longitudinal observational research, and advanced biomarker analyses.

• Rheumatology
• Juvenile idiopathic arthritis
• Rheumatoid arthritis
• +۴ مورد دیگر

Dr. Cameron Stewart is a Research Team Leader at CSIRO's Health & Biosecurity Business Unit, based at the Australian Centre for Disease Preparedness (ACDP) in Geelong, Victoria. His research focuses on host-pathogen interactions to develop novel intervention strategies, with expertise in host-encoded microRNAs as biomarkers for infection detection and disease severity forecasting. Dr. Stewart's educational background includes: PhD in 2007 from The University of Melbourne Bachelor of Science (Honours) in 2003 from The University of Melbourne Post-doctoral fellowship at Harvard Medical School (2007-2008) His primary research areas encompass host-pathogen interactions, biomarker discovery for infectious diseases, and the identification of host molecules as therapeutic targets. Notably, his team was the first to comprehensively profile microRNA responses to COVID-19 and has characterized proteins such as ILRUN. This work bridges microbiology, virology, immunology, and functional genomics to advance disease diagnostics and therapeutics. Dr. Stewart has received several prestigious awards, including: CSIRO Chairman's Medal (2020) Corporate Citizen Award (Group) from CSIRO ACDP (2020) CSIRO Julius Career Award (2017-2019) CSIRO Livestock Industries Excellence in Young Scientists Award (2010) His lab, the Host Response Team, is supported by multiple active grants from national and international bodies including the Department of Health, Department of Agriculture, Water and Environment, NHMRC, and Therapeutics Innovation Australia. These grants fund research on diagnostics for Johne's disease, Mycoplasma bovis, Hendra virus, and host responses to SARS-CoV-2. The Host Response Team operates within the high-containment facilities of the Australian Centre for Disease Preparedness, enabling cutting-edge research on dangerous pathogens. The team actively collaborates with institutions such as Monash University and the Chinese Academy of Sciences, and participates in networks like the Biosafety Level 4 Zoonotic Laboratory Network.

• Host-Pathogen Interactions
• Biomarker Discovery
• Infectious Disease Diagnostics
• +۴ مورد دیگر

W. Mark Saltzman is the Sterling Professor of Biomedical Engineering and Professor of Cellular and Molecular Physiology and of Chemical Engineering at Yale University. He serves as Affiliated Faculty at the Yale Institute for Global Health and was the founding chair of Yale's Department of Biomedical Engineering for 12 years. From 2016-2022, he was Head of Jonathan Edwards College, one of Yale's residential colleges. His academic journey includes faculty positions at Johns Hopkins University and Cornell University before joining Yale in 2002 as the Goizueta Foundation Professor of Chemical and Biomedical Engineering. Professor Saltzman's research has profoundly impacted drug delivery, biomaterials, nanobiotechnology, and tissue engineering, with over 350 research papers and patents. His work integrates mathematical modeling with experimental approaches to develop innovative delivery systems. Key contributions include developing mathematical models for drug delivery system design, creating methods for brain tumor drug delivery, producing the first controlled delivery systems for nerve growth factors, and developing materials for DNA/RNA delivery. His lab's current focus spans RNA therapeutics for cancer, in utero gene editing for cystic fibrosis, and targeted nanoparticle delivery systems. His recent publications (2024-2025) demonstrate a strong emphasis on translational applications, particularly in cancer therapy and genetic disorders. These works showcase his lab's expertise in nanoparticle engineering, with research spanning from fundamental studies of nanoparticle-cell interactions to preclinical studies in nonhuman primates. The interdisciplinary nature of his work is evident in collaborations across engineering, medicine, and basic science departments at Yale. Elected member of the US National Academy of Medicine Elected member of the US National Academy of Engineering Sterling Professor of Biomedical Engineering (2025) Author of three textbooks: 'Biomedical Engineering,' 'Tissue Engineering,' and 'Drug Delivery' Professor Saltzman has mentored 43 doctoral students and 27 postdoctoral associates throughout his career, with many becoming independent researchers at leading institutions. His research group maintains active collaborations with clinicians and scientists across Yale, particularly in cystic fibrosis research, cancer therapy, and fetal medicine. The Saltzman Research Group continues to push the boundaries of drug and gene delivery technology, with recent work focusing on RNA therapeutics, in utero treatments, and precision targeting of nanoparticles to specific cell populations. The lab maintains strong connections with Yale's Cancer Center, Center for RNA Science and Medicine, and Vascular Biology and Therapeutics Program, facilitating translation of engineering approaches to clinical applications. Current research directions include developing nanoparticle systems for cancer immunotherapy, in utero gene editing, and targeted delivery to specific organ systems.

• Drug Delivery
• Biomaterials
• Nanobiotechnology
• +۷ مورد دیگر

Joan Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry at Yale School of Medicine, where she has made groundbreaking contributions to RNA biology. She leads the Steitz Lab, which is affiliated with multiple Yale research centers including the Yale Cancer Center, Yale Stem Cell Center, and the Center for RNA Science and Medicine. Yale School of Medicine, Department of Molecular Biophysics and Biochemistry (Primary) Yale Cancer Center Yale Stem Cell Center Yale Combined Program in the Biological and Biomedical Sciences (BBS) Center for RNA Science and Medicine Dr. Steitz earned her BS from Antioch College (1963) and PhD from Harvard University (1967), followed by postdoctoral work at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England. She joined Yale as an assistant professor and progressed to become a Sterling Professor, one of Yale's highest academic honors. Her research focuses on RNA-protein complexes, particularly small nuclear ribonucleoproteins (snRNPs) that play critical roles in pre-mRNA splicing. The lab investigates how these complexes recognize intron signals and assemble into functional spliceosomes. Recent work has explored stress-induced transcriptional readthrough, RNA stability mechanisms involving poly(A) tails, and the functions of viral noncoding RNAs from herpesviruses. Analysis of Dr. Steitz's recent publications reveals a strong emphasis on RNA structure-function relationships, viral-host interactions, and the molecular mechanisms of RNA processing. Her work spans structural biology, virology, and molecular genetics, with applications to understanding human diseases including cancer. Warren Alpert Prize (2021) Wolf Prize in Medicine (2021) Watson Prize (2021) Medal Prize Lecture (2021) Honorary Doctor of Science (2021) Dr. Steitz actively mentors students and postdocs, with numerous trainees appearing as co-authors on her publications. Her lab maintains strong collaborations across Yale and with international researchers, as evidenced by her extensive publication record. She has also been a prominent advocate for gender diversity in STEM fields, co-authoring influential papers on improving representation of women in science. The Steitz Lab maintains active research programs in RNA structure, splicing mechanisms, viral noncoding RNAs, and stress responses, with ongoing projects examining how RNA-protein interactions govern gene expression in both normal and disease states.

• RNA-Protein Complexes
• Gene Expression
• Noncoding RNAs
• +۷ مورد دیگر

Dimitra P. Vageli is a Research Scientist in the Department of Neurology at Yale School of Medicine with extensive expertise in molecular biology, molecular pathology, and cancer biology. She is affiliated with the Yale Cancer Center, Cancer Signaling Networks Program, Center for Neuroscience and Regeneration Research, and the Larynx Lab, where she leads research on head and neck cancer mechanisms and neurological disorders. Her academic background includes: Bachelor's Degree in Sciences, specializing in Biology from the University of Patras, Greece Post-graduate Scholarship in Radiation Biology and Radiation Physics from National Centre for Scientific Research 'Demokritos' in Athens, Greece Ph.D. in Molecular Oncology and Biotechnology from the Medical School of Crete, University of Crete, Greece (1998) Dr. Vageli's research program focuses on: Mechanisms of neoplastic transformation under exposure to risk factors like bile reflux and tobacco smoke Role of transcription factors (NF-κB, STAT3, EGFR) in early oncogenic events miRNA research for diagnostic biomarkers in cancer Investigating the role of ion channels in neurological disorders Chronic inflammation pathways in carcinogenesis Her publication record demonstrates consistent scholarly contributions with numerous articles in high-impact journals. Her research has evolved from initial groundbreaking work on bile reflux and hypopharyngeal carcinogenesis to broader investigations of molecular pathways, biomarker discovery, and connections between neurological disorders and cancer biology. Recent work includes systematic reviews on biomarkers in atherosclerosis and glioblastoma, reflecting expanding research interests. Her notable recognition includes: Author Service Award 2025 Springer Nature Editor of Distinction Award 2025 Ohse Research Awards (2013-2014 and 2014-2015) Dr. Vageli maintains active collaborations both within Yale and internationally, particularly with Greek research institutions. Her work bridges basic molecular research with translational applications, employing advanced technologies including whole transcriptome and small RNA sequencing analyses. Her research program continues to advance understanding of cancer mechanisms and identify potential targets for prevention, diagnosis, and treatment. Her laboratory work in the Larynx Lab utilizes in vivo models, molecular biology techniques, and advanced sequencing technologies to investigate the progressive effects of carcinogenic exposures on mucosal tissues, with particular emphasis on DNA damage, miRNA deregulation, and histological changes during early cancer development.

• Molecular Biology
• Molecular Pathology
• Cancer Biology
• +۷ مورد دیگر

Derek Stirewalt is a Professor in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center and an Associate Professor in the Division of Hematology and Oncology at the University of Washington. He serves as Director of both the Fred Hutch/UW Hematopoietic Diseases Repository and the Co-operative Center of Excellence in Hematology Hematopoietic Cell Procurement and Processing Services. Dr. Stirewalt has been an active member of Fred Hutch's transplant program for over 20 years and is involved with the National Comprehensive Cancer Network Guideline Committee for Senior Adult Oncology. Education: M.D., University of North Carolina at Chapel Hill (1992) Residency, University of North Carolina Fellowship in Hematology-Oncology, University of Washington Dr. Stirewalt's research focuses on the molecular changes in blood stem cells during aging and their relationship to leukemia development. His work specifically examines FLT3 and NPM1 mutations in acute myeloid leukemia (AML), identifying novel biomarkers for hematopoietic malignancies, and understanding how aging contributes to cancer development. He employs cutting-edge technologies including next-generation sequencing, proteomics, and transfection/transduction models to analyze DNA, RNA, and protein expression patterns. Analysis of Dr. Stirewalt's recent publications reveals a strong focus on AML molecular biology, particularly regarding FLT3 and NPM1 mutations, risk stratification, and aging-related changes in hematopoietic malignancies. His research spans basic science investigations of molecular pathways to clinical applications in risk prediction and treatment response. The publications demonstrate collaborative work with major cancer research groups including SWOG, Children's Oncology Group, and the National Cancer Institute. Leadership Roles: Director, Fred Hutch/UW Hematopoietic Diseases Repository Director, Co-operative Center of Excellence in Hematology Hematopoietic Cell Procurement and Processing Services Member, NCCN Guideline Committee for Senior Adult Oncology Dr. Stirewalt has received continuous research funding supporting his investigations into AML biology and aging. His laboratory works closely with multiple internal and external investigators at the National Cancer Institute, Southwest Oncology Group, and Children's Oncology Group. The Fred Hutch/UW Hematopoietic Diseases Repository and CCEH resources he directs provide critical samples to researchers nationwide. Dr. Stirewalt leads a research team focused on understanding the molecular basis of hematopoietic malignancies, particularly how aging affects disease development and treatment response in AML. His laboratory has made significant contributions to recognizing FLT3 internal tandem duplications and NPM1 mutations as key prognostic factors in AML.

• Acute Myeloid Leukemia
• Hematopoietic Stem Cell Aging
• Molecular Biomarkers
• +۵ مورد دیگر

Dorte Maegaard Tholstrup is a Clinical Associate Professor at the Department of Clinical Medicine, based at Blegdamsvej 3, 2200 København N. Her primary affiliation involves clinical research in hematology and oncology, with a focus on therapeutic interventions and diagnostic methodologies. Research Focus: Her work spans lymphoma pathophysiology, stem cell transplantation protocols, and biomarker discovery. Key areas include: Chemotherapy toxicity mitigation using agents like Semaglutide Molecular diagnostics through circulating microRNAs Epigenetic prognostic markers in lymphoma Immunological recovery post-chemotherapy Publication Trends: Recent articles demonstrate a progression toward interventional clinical trials (2024) building on earlier foundational work in lymphoma biomarkers (2017-2020) and immune system recovery (2009). Her research consistently addresses translational gaps in hematologic malignancies.

• Hematology
• Oncology
• Lymphoma Research
• +۲ مورد دیگر

Katrine Toft Nielsen serves as an Assistant Professor at the University of Copenhagen's Department of Veterinary Clinical Sciences, specifically within the Section of Large Animal Medicine, Surgery and Reproduction. Her research focuses on molecular aspects of equine diseases, particularly investigating microRNA biomarkers for diagnostic applications in horse health. Her primary research interests include equine parasitology, with special emphasis on Strongylus vulgaris (bloodworm) infections, microRNA profiling as diagnostic tools, and molecular mechanisms of equine gastrointestinal diseases. Nielsen's work bridges basic molecular biology with clinical veterinary applications, aiming to develop more precise diagnostic methods for equine conditions. Analysis of her recent publications (2021-2025) reveals a consistent research trajectory focused on microRNA applications in equine parasitology, particularly Strongylus vulgaris infections. Her work spans diagnostic biomarker discovery, parasite molecular biology, and clinical applications of molecular diagnostics in veterinary medicine, demonstrating interdisciplinary expertise connecting molecular biology with clinical veterinary practice. Nielsen actively collaborates with researchers across the University of Copenhagen's veterinary departments, contributing to the institution's strong reputation in equine medicine and parasitology research. Her work appears in reputable veterinary science journals including Veterinary Journal, Veterinary Parasitology, and International Journal for Parasitology.

• Equine parasitology
• MicroRNA research
• Veterinary diagnostics
• +۴ مورد دیگر

Fritsch A. is an active researcher publishing across multiple medical disciplines including oncology, pain management, plastic surgery, and AI applications in medicine. The publication record from 2025 indicates ongoing research activity across various clinical domains. Research interests span several key areas: clinical oncology with focus on ovarian cancer detection techniques; pain management research particularly regarding diabetic neuropathy; plastic and reconstructive surgery with emphasis on microsurgical techniques and resident training; and emerging applications of artificial intelligence in patient care after surgical procedures. The work demonstrates a strong clinical research focus with translational applications. The publication portfolio shows a trend toward interdisciplinary research, particularly at the intersection of traditional medical specialties and emerging technologies. Several publications address methodological improvements in clinical practice, including novel imaging techniques, drug monitoring approaches, and evaluation of new therapeutic interventions. The research often involves multi-institutional collaborations as indicated by the author lists. Active participation in clinical trials research, particularly in pain management Contributions to surgical education methodology Exploration of AI applications in postoperative patient care Methodological improvements in drug concentration monitoring

• Oncology
• Nuclear Medicine
• Pain Management
• +۳ مورد دیگر

Thomas Litman is a Professor in the Department of Immunology and Microbiology at the University of Copenhagen's Faculty of Health and Medical Sciences, where he leads bioinformatics research at the Skin Immunology Research Center. With expertise spanning multiple omics technologies, he applies computational approaches to understand complex biological systems, particularly in the context of inflammatory skin diseases and cancer biology. Dr. Litman earned his PhD from the University of Copenhagen in 1996 with research focused on 'The multidrug resistant phenotype - a comparative study.' His academic journey has positioned him at the intersection of computational biology and medical research. Professor Litman's research centers on medical bioinformatics, with particular emphasis on inflammatory skin diseases including atopic dermatitis, psoriasis, and cutaneous T-cell lymphoma. He investigates multidrug resistance in cancer, utilizing transcriptomics, metabolomics, microbiome analysis, and proteomics to develop integrated 'skinomics' approaches. His work focuses on identifying molecular biomarkers with diagnostic, prognostic, and predictive value, especially for characterizing endotypes of inflammatory skin conditions. Through structural bioinformatics and translational research using cellular models, 3-D models, and clinical data, he bridges computational analysis with real-world medical applications. His recent publication record demonstrates a strong focus on applying multi-omics approaches to dermatological conditions, with significant contributions to understanding chronic hand eczema, basal cell carcinoma, and cutaneous T-cell lymphoma. His work increasingly integrates clinical data with molecular profiling to identify biomarkers and therapeutic targets, reflecting a trend toward more personalized approaches in dermatology and oncology. Professor Litman actively supervises bachelor's, master's, and PhD students in applied bioinformatics, encouraging the next generation of researchers to explore the 'data jungle' through computational analysis. His research is supported by collaborations with LEO Pharma and other industry partners, facilitating translational research from bench to bedside.

• Medical bioinformatics
• Inflammatory skin diseases
• Multidrug resistance in cancer
• +۸ مورد دیگر

Prof. Dr. Jens Allmer is a full Professor of Medical Informatics and Bioinformatics at Ruhr West University of Applied Sciences (HRW) in Mülheim an der Ruhr, Germany. He previously held academic positions as Cluster Leader at Wageningen University and Research in the Netherlands (2017-2018) and as Assistant and Associate Professor at Izmir Institute of Technology in Turkey (2008-2016). His academic journey began with a PhD in Biology with distinction from the University of Münster in 2006. Prof. Allmer's research spans multiple omics disciplines with a primary focus on microRNA regulation and pathogen-host interactions. He employs machine learning techniques to explore these complex biological systems. His work has evolved from foundational bioinformatics methods to sophisticated integrative analyses, particularly in proteogenomics and computational miRNomics. He has made significant contributions to understanding microRNA detection algorithms, proteogenomic peptide mapping, and the development of comprehensive frameworks for omics data analysis. His recent publications demonstrate a strong trend toward integrative approaches that combine multiple data types, with increasing emphasis on machine learning applications in bioinformatics. The research spans from fundamental database development for noncoding RNAs to clinical applications in disease mechanisms, particularly in HIV infection and cancer pathways. His work shows consistent progression from method development to application in biological and medical contexts. Outstanding Young Scientist in Bioinformatics by the Turkish Academy of Sciences (2010) EMBO Short Term Fellowship Award (2013) DAAD Research Stays for University Academics and Scientists (2013, declined) Outstanding Young Researcher, Turkish Academy of Science (2010) Prof. Allmer has advised numerous doctoral and master's students throughout his career, primarily during his tenure at Izmir Institute of Technology. He has secured substantial research funding, with over 650,000 euros received for his projects. His teaching portfolio includes courses in medical informatics, bioinformatics, data mining, machine learning, and database systems across multiple institutions in Germany, Turkey, and through ERASMUS programs. He maintains active collaborations with researchers across Europe and continues to contribute significantly to both theoretical and applied aspects of bioinformatics.

• Medical Informatics
• Bioinformatics
• Omics Disciplines
• +۵ مورد دیگر